【摘要】：目的:了解利奈唑胺治療新生兒感染性疾病的研究進(jìn)展。方法:查閱近年來(lái)國(guó)內(nèi)外相關(guān)文獻(xiàn),就利奈唑胺的作用機(jī)制、藥動(dòng)學(xué)特征和在新生兒感染性疾病中的應(yīng)用的研究進(jìn)行歸納和總結(jié)。結(jié)果和結(jié)論:利奈唑胺未被完全批準(zhǔn)用于新生兒,但多項(xiàng)研究顯示出利奈唑胺治療新生兒耐藥革蘭氏陽(yáng)性菌感染安全、有效,尤其是對(duì)新生兒敗血癥的治療,利奈唑胺與萬(wàn)古霉素療效相當(dāng)。在新生兒中,利奈唑胺的給藥可根據(jù)疾病、出生時(shí)體質(zhì)量、胎齡和日齡等因素選擇給藥方案。新生兒中利奈唑胺的不良反應(yīng)發(fā)生率較萬(wàn)古霉素低,但由于會(huì)引起骨髓抑制,用藥期間需密切監(jiān)測(cè)全血細(xì)胞計(jì)數(shù)。我國(guó)尚需大樣本的研究用于評(píng)估利奈唑胺在新生兒感染性疾病治療中的療效和安全性。
[Abstract]:Objective: to investigate the progress in the treatment of neonatal infectious diseases with linidazole. Methods: referring to the related literatures at home and abroad in recent years, the mechanism, pharmacokinetic characteristics and application in neonatal infectious diseases were summarized and summarized. Results and conclusion: Linezolide has not been fully approved for neonatal use, but several studies have shown that it is safe and effective in the treatment of neonatal drug-resistant gram-positive bacteria infection, especially for neonatal septicemia. Linezolamine and vancomycin have the same therapeutic effect. In newborns, the administration of linazolamide can be selected according to the disease, birth weight, gestational age and age. The incidence of adverse reactions in newborn infants was lower than that of vancomycin, but the whole blood cell count should be closely monitored during the treatment because of myelosuppression. In our country, a large sample study is needed to evaluate the efficacy and safety of linazolamide in the treatment of neonatal infectious diseases.
【作者單位】： 安徽醫(yī)科大學(xué)第三附屬醫(yī)院藥學(xué)部;
【分類(lèi)號(hào)】：R722.13

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉偉;陳玲;專(zhuān)晨昱;;利奈唑胺治療新生兒敗血癥的臨床療效和安全性[J];中國(guó)當(dāng)代兒科雜志;2015年04期

2 屠志琴;屠芳蘭;延曉曦;;NICU患兒感染病原菌分布及耐藥性分析[J];中華醫(yī)院感染學(xué)雜志;2014年24期

3 許平;吳銀弟;石微娜;;口服利奈唑胺治療新生兒革蘭陽(yáng)性球菌敗血癥的臨床分析[J];臨床合理用藥雜志;2014年24期

4 徐海莉;艾銀鳳;段志嫻;;利奈唑胺對(duì)新生兒血流感染患兒的療效評(píng)價(jià)[J];抗感染藥學(xué);2014年03期

5 唐曉娟;馮星;;1606例新生兒敗血癥病原菌分布及其耐藥性分析[J];臨床兒科雜志;2014年03期

6 鐘巧;李暉;高曉玲;劉s，

本文編號(hào)：2446171